Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119


Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements.

Childs E, Roche DJ, King AC, de Wit H.

Alcohol Clin Exp Res. 2012 May;36(5):906-14. doi: 10.1111/j.1530-0277.2011.01675.x. Epub 2012 Feb 16.


Varenicline reduces alcohol self-administration in heavy-drinking smokers.

McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E.

Biol Psychiatry. 2009 Jul 15;66(2):185-90. doi: 10.1016/j.biopsych.2009.01.029. Epub 2009 Feb 27.


Varenicline decreases alcohol consumption in heavy-drinking smokers.

Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL.

Psychopharmacology (Berl). 2012 Oct;223(3):299-306. doi: 10.1007/s00213-012-2717-x. Epub 2012 May 1.


Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption.

Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR.

J Neurosci. 2010 Jul 28;30(30):10169-76. doi: 10.1523/JNEUROSCI.2601-10.2010.


Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals.

Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H.

Psychopharmacology (Berl). 2014 Sep;231(18):3799-807. doi: 10.1007/s00213-014-3518-1. Epub 2014 Mar 20.


Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice.

Kamens HM, Andersen J, Picciotto MR.

Psychopharmacology (Berl). 2010 Mar;208(4):613-26. doi: 10.1007/s00213-009-1759-1.


A preliminary investigation of varenicline for heavy drinking smokers.

Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS.

Psychopharmacology (Berl). 2011 Jun;215(4):655-63. doi: 10.1007/s00213-010-2160-9. Epub 2011 Jan 11.


Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization.

Gubner NR, McKinnon CS, Phillips TJ.

Alcohol Clin Exp Res. 2014 Dec;38(12):3033-42. doi: 10.1111/acer.12588.


Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.


Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.


Effects of varenicline on ethanol- and food-maintained responding in a concurrent access procedure.

Ginsburg BC, Lamb RJ.

Alcohol Clin Exp Res. 2013 Jul;37(7):1228-33. doi: 10.1111/acer.12085. Epub 2013 Feb 15.


The effects of varenicline on alcohol seeking and self-administration in baboons.

Kaminski BJ, Weerts EM.

Alcohol Clin Exp Res. 2014 Feb;38(2):376-83. doi: 10.1111/acer.12233. Epub 2013 Aug 19.


Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.

Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED.

Psychopharmacology (Berl). 2014 Oct;231(19):3843-53. doi: 10.1007/s00213-014-3519-0. Epub 2014 Apr 15.


Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.

Sofuoglu M, Herman AI, Mooney M, Waters AJ.

Psychopharmacology (Berl). 2009 Nov;207(1):153-62. doi: 10.1007/s00213-009-1643-z. Epub 2009 Aug 20.


Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers.

Vatsalya V, Gowin JL, Schwandt ML, Momenan R, Coe MA, Cooke ME, Hommer DW, Bartlett S, Heilig M, Ramchandani VA.

Int J Neuropsychopharmacol. 2015 Jul 25;18(12). pii: pyv068. doi: 10.1093/ijnp/pyv068.


Bidirectional interactions between acute psychosocial stress and acute intravenous alcohol in healthy men.

Childs E, O'Connor S, de Wit H.

Alcohol Clin Exp Res. 2011 Oct;35(10):1794-803. doi: 10.1111/j.1530-0277.2011.01522.x. Epub 2011 Jul 18.


A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.

Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL.

Neurology. 2012 Feb 21;78(8):545-50. doi: 10.1212/WNL.0b013e318247cc7a. Epub 2012 Feb 8. Erratum in: Neurology. 2012 Jul 31;79(5):488.


Varenicline improves mood and cognition during smoking abstinence.

Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM, Siegel S, Lerman C.

Biol Psychiatry. 2009 Jan 15;65(2):144-9. doi: 10.1016/j.biopsych.2008.08.028. Epub 2008 Oct 8.


Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats.

Sotomayor-Zárate R, Gysling K, Busto UE, Cassels BK, Tampier L, Quintanilla ME.

Psychopharmacology (Berl). 2013 May;227(2):287-98. doi: 10.1007/s00213-013-2974-3. Epub 2013 Jan 24.

Items per page

Supplemental Content

Write to the Help Desk